Principal Investigator
Fernando Corrales Medina
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20220007
Clinical Trial Summary
PREDICT*- A multicenter, prospective, open-label, clinical study to assess the effect of using a new risk score approach to select the most appropriate prophylaxis regimen for reaching a favorable outcome, when hemophilia A patients switch from standard half-life products to damoctocog alfa pegol (Jivi)
*(PRediction factors for optimal Efficacy and Dosingreg regimen when swItChing from SHL To EHL)
Phase
N/A
Funding Agency/Sponsor
Industry
Disease
Other
Contact Information
Study Contact
Leandro Pisani
Phone Number
+1 (305) 2436925
Email
lfp34@miami.edu